Global Pharma And Biotech R&D Increase Will Build Value

Published
06 Apr 25
Updated
15 Aug 25
AnalystConsensusTarget's Fair Value
US$5.50
65.6% undervalued intrinsic discount
15 Aug
US$1.89
Loading
1Y
21.2%
7D
0%

Author's Valuation

US$5.5

65.6% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 1.29%

Shared on24 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has decreased future PE multiple from 4.7x to 4.2x.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 10%

AnalystConsensusTarget has increased future PE multiple from 4.0x to 4.7x and decreased shares outstanding growth rate from 0.3% to 0.1%.